Search results for: 'PCR Reagent Market for Research Applications and Clinical Diagnostics'

This Frost & Sullivan research service discusses advances in AI integration in Molecular Diagnostics, highlights key advantages of incorporating AI in the diagnostics workflow and roadblocks that have prevented it from becoming mainstream. While AI is widely used in radiology- and pathology-based diagnostics, its adoption is gradually increasing in...

14 Feb 2025  |  Global  |  Market Research

Proteomics Research Tools and Diagnostics Market, Global, 2024-2030

The Proteomics Industry is Experiencing Transformational Growth Due to Advancements in Proteomics Profiling and Biomarker Discovery

Infographics

×

In the study, Frost & Sullivan examines the global proteomics research tools and diagnostics market, covering different product types, end users, and technologies. The market is projected to register high growth between 2024 and 2030, reaching significant revenue milestones, largely driven by the research and pharmaceutical segments. The increasing...

Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...

31 Jul 2023  |  North America  |  Market Research

Global Oncology Diagnostics in IVD Growth Opportunities

By Leveraging Data-driven Solutions, Co-development Opportunities, and Assay Innovation, Clients Can Experience Enhanced Product Performance, Cost-effectiveness, and Improved Decision-making Capabilities

Infographics

×

The global oncology diagnostics in IVD market is expected to witness significant growth, driven by an increase in cancer incidence, technological developments in diagnostic tests, the growing number of screening tests, and supportive government initiatives. Owing to the intense competition in the market, the most prominent companies are investing h...

The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiol...

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, presenting opportunities for innovation. There has been a...

As global clinical pipelines witness a surge in complex novel therapies, there is a general inclination toward improving trial design through adaptive trial designs with technology-enabled solutions for planning and execution. Artificial intelligence (AI) is gaining large-scale recognition in terms of supporting decentralized trial designs and allo...

This report examines how decentralized clinical trials (DCTs), enabled by blockchain, digital twins, and artificial intelligence, are reshaping global clinical research. It traces the shift from site-centric to patient-centric models and quantifies the growing scale, globalization, and complexity of clinical trials that make decentralization necess...

According to the National Institute of Health (NIH), there are more than 80 types of autoimmune diseases, of which less than 30 are diagnosable. Being 1 of the top 10 causes of death in the United States, there is a critical need in the market for the diagnosis and the treatment of both systemic diseases, such as lupus and rheumatoid arthritis, as ...